Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
Primary Purpose
Osteoporosis, Osteopenia
Status
Completed
Phase
Phase 2
Locations
Poland
Study Type
Interventional
Intervention
Standardized Extract of Olive Polyphenols
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Osteoporosis focused on measuring osteoporosis, osteopenia, olive extract, oleuropein
Eligibility Criteria
Inclusion Criteria:
- Signed written informed consent
- Gender female
- Between 50-70 years of age
- At least 2 years post menopause
- Bone mineral density (BMD) < or equal to -1.5 and > or equal to -2.5 SD% Young Adult
- Patients with stabilised food habits
- Patients able to understand the nature of the study and able to give signed written informed consent.
Exclusion Criteria:
- Patients with any diseases affecting bone tissue e.g. primary hyperparathyroidism.
- Patients during any therapy affecting bone tissue e.g. HRT, corticosteroids.
- Patients with any associated illness of sufficient severity, or clinically relevant abnormalities in the pre-study screening, which in the opinion of the investigator would make them unsuitable for inclusion in the study, e.g. severe heart failure, severe ischaemic heart disease etc.
- Planned hospitalisation (major surgery) during the study.
- Patients who have any known allergy or intolerance to any compound in the test product.
- Patients who are unwilling or unable to comply with the study protocol for any other reason.
Sites / Locations
- Osteoporosis Outpatient of the Institute of Agricultural Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
Placebo (starch) + 1000 mg of calcium per day.
Outcomes
Primary Outcome Measures
Serum levels of Osteocalcin and CTX will be used as bone turnover markers
Secondary Outcome Measures
Bone mineral density as measured by DEXA in lumbar spine and total hip
hs-CRP and IL-6 in serum as inflammation markers
ORAC values in serum as oxidative stress marker
Total cholesterol, HDL-C, LDL-C, triglycerides in serum as CVD-risk markers.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00789425
Brief Title
Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
Official Title
A Randomised, Double Blind, Parallel Group, 12-month Comparison of a Standardized Olive Extract With Placebo in Postmenopausal Women With Decreased Bone Mineral Density
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
BioActor
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether the intake of a daily dosage of standardized olive extract provides any protection against bone loss.
Detailed Description
Apart from estrogen deficiency, the early postmenopausal period is also characterised by an increasing inflammatory and oxidant status, which further contributes to the development of osteoporosis/osteopenia. The link between systemic inflammation and osteoporosis has only been established recently as it was found that higher circulating hsCRP levels are associated with lower bone mineral density in both healthy pre- and postmenopausal women. Furthermore, it was already known for a long time that one of the most important cytokines implicated in the pathogenesis of various metabolic bone diseases, including postmenopausal osteoporosis, is interleukin (IL)-6, which is produced by osteoblasts, monocytes and T-cells.
Olive oil is the principle fat source of the traditional Mediterranean diet, a diet that has been associated with a low incidence of some diseases, including coronary heart disease and osteoporosis. In addition to the main ingredient (ie. oleic acid) extra virgin olive oil also contains phenolic compounds, such as oleuropein- and ligstroside-aglycones and their derivatives. They are formed in olives by enzymatic removal of glucose from the polar parent compound oleuropein-glycoside. A Mediterranean diet rich in olive oil supplies 10 - 20 mg of phenols per day.
The main metabolic attribute of oleuropein is that it exerts both antioxidant and anti-inflammatory activity by lowering the levels of proinflammatory cytokines like IL-1, IL-6 or TNF-alpha. By inhibiting osteoclast activity, this may result in lowering the rate of bone resorption and, at least in part, protect against osteoporosis development.
Formulated as a capsule it is expected that the compliance and tolerability will be improved compared to the liquid administration. The present study is designed to investigate the effect of 250 mg of a standardized extract of olive polyphenols per day on bone loss in postmenopausal women with decreased bone mass (osteopenia) .
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis, Osteopenia
Keywords
osteoporosis, osteopenia, olive extract, oleuropein
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo (starch) + 1000 mg of calcium per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Standardized Extract of Olive Polyphenols
Intervention Description
Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.
A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Primary Outcome Measure Information:
Title
Serum levels of Osteocalcin and CTX will be used as bone turnover markers
Time Frame
0, 3, 6, and 12 months
Secondary Outcome Measure Information:
Title
Bone mineral density as measured by DEXA in lumbar spine and total hip
Time Frame
0 and 12 months
Title
hs-CRP and IL-6 in serum as inflammation markers
Time Frame
0, 6, and 12 months
Title
ORAC values in serum as oxidative stress marker
Time Frame
0, 6, and 12 months
Title
Total cholesterol, HDL-C, LDL-C, triglycerides in serum as CVD-risk markers.
Time Frame
0, 6, and 12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Signed written informed consent
Gender female
Between 50-70 years of age
At least 2 years post menopause
Bone mineral density (BMD) < or equal to -1.5 and > or equal to -2.5 SD% Young Adult
Patients with stabilised food habits
Patients able to understand the nature of the study and able to give signed written informed consent.
Exclusion Criteria:
Patients with any diseases affecting bone tissue e.g. primary hyperparathyroidism.
Patients during any therapy affecting bone tissue e.g. HRT, corticosteroids.
Patients with any associated illness of sufficient severity, or clinically relevant abnormalities in the pre-study screening, which in the opinion of the investigator would make them unsuitable for inclusion in the study, e.g. severe heart failure, severe ischaemic heart disease etc.
Planned hospitalisation (major surgery) during the study.
Patients who have any known allergy or intolerance to any compound in the test product.
Patients who are unwilling or unable to comply with the study protocol for any other reason.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafal Filip, MD PhD
Organizational Affiliation
Institute of Agricultural Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Osteoporosis Outpatient of the Institute of Agricultural Medicine
City
Lublin
ZIP/Postal Code
20-950
Country
Poland
12. IPD Sharing Statement
Citations:
PubMed Identifier
25560820
Citation
Filip R, Possemiers S, Heyerick A, Pinheiro I, Raszewski G, Davicco MJ, Coxam V. Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia. J Nutr Health Aging. 2015 Jan;19(1):77-86. doi: 10.1007/s12603-014-0480-x.
Results Reference
derived
Learn more about this trial
Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
We'll reach out to this number within 24 hrs